It’s too early to know whether the L452R version of SARS-CoV-2 is highly infectious like the B.1.1.7 UK variant that is also spreading around the US.

A large study of UK healthcare workers finds that immunity after coronavirus infection lasts for months, but those with antibodies may still be able to carry and spread the virus upon reexposure.

Few peer-reviewed clinical papers on the pandemic contained original data, and many of those that did had poor experimental design.

Zoo officials say the captive primates are recovering, but scientists worry the virus could spread quickly through dwindling wild populations.

The UCSF microbiologist pioneered investigations into the deadly disease starting in the late 1960s that have led to the near eradication of trachoma, a chlamydia-related eye infection.

See a news report on a study of expectant mothers with SARS-CoV-2 infections.

The immunosuppressive drugs tocilizumab and sarilumab improved survival and recovery time of intensive care COVID-19 patients, according to a preprint.

From new treatments to an investigation into the virus’s origins, here are some of the developments we can expect this year.

An engineered coronavirus with the N501Y mutation—one of many mutations present in the emerging B.1.1.7 and 501.V2 variants of the coronavirus—is neutralized by the sera of COVID-19 vaccine recipients.